# JBZ-001

Source: https://onco.cc/drugs/jbz-001/  
OnCo record `jbz-001` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

JBZ-001 is an experimental oral small-molecule inhibitor from Jabez Biosciences, in phase 1 trials for advanced solid tumours and non-Hodgkin lymphoma.

## Summary

JBZ-001 is an oral small-molecule inhibitor from Jabez Biosciences. An oral inhibitor of dihydroorotate dehydrogenase (DHODH), an enzyme cells use to make pyrimidine building blocks. Its furthest stage is phase 1, for advanced solid tumours and non-Hodgkin lymphoma. ClinicalTrials.gov registers it in one study linked below. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: JBZ-001
- Modality: Oral small-molecule inhibitor
- Mechanism: An oral inhibitor of dihydroorotate dehydrogenase (DHODH), an enzyme cells use to make pyrimidine building blocks.

## Sources

- Jabez Biosciences: jabezbio.com: https://www.jabezbio.com/
- Jabez Biosciences: jabezbio.com: https://www.jabezbio.com/
- ClinicalTrials.gov: trials of JBZ-001: https://clinicaltrials.gov/search?intr=JBZ-001

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [DHODH](https://onco.cc/targets/dhodh/)
- companies: [Jabez Biosciences](https://onco.cc/companies/jabez-biosciences/)
- trials: [Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies](https://onco.cc/trials/nct06801002/)

---
JSON: https://onco.cc/api/v1/entities/jbz-001.json